SCHEMBL18930227

SCHEMBL18930227

NC(=O)c1ccc(C[C@@H](N)CO)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.53
ENPEP Q07075 2/20 0.53
PLA2G10 O15496 1/20 0.50
PLA2G2A P14555 1/20 0.50
PARP10 Q53GL7 6/20 0.47
TPH1 P17752 1/20 0.45
CYP17A1 P05093 1/20 0.43
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
PARP15 Q460N3 1/20 0.42
PARP14 Q460N5 1/20 0.42
PARP16 Q8N5Y8 1/20 0.42
PARP11 Q9NR21 1/20 0.42
PARP4 Q9UKK3 1/20 0.42
SLC6A4 P31645 1/20 0.42
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
PARP1 P09874 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21144940 0.98 ANPEP (0.51) ANPEPENPEPPLA2G10PLA2G2APARP10
Hydrochloric Acid SCHEMBL21144942 0.98 ANPEP (0.51) ANPEPENPEPPLA2G10PLA2G2APARP10
SCHEMBL14023887 0.85 ANPEP (0.50) ANPEPENPEPPLA2G10PLA2G2APARP10
SCHEMBL11110809 0.85 SLC6A4 (0.53) ANPEPENPEPPLA2G10PLA2G2APARP10
SCHEMBL18920569 0.84 ANPEP (0.73) ANPEPENPEPTPH1ALDH1A1TSHR
SCHEMBL12230921 0.83 DPP4 (0.50) PLA2G10PLA2G2APARP10CYP17A1ALDH1A1
Hydrochloric Acid SCHEMBL21144830 0.82 ANPEP (0.71) ANPEPENPEPTPH1ALDH1A1TSHR
SCHEMBL18307031 0.82 KMT2A (0.55) ANPEPENPEPTPH1ALDH1A1KMT2A
Hydrochloric Acid SCHEMBL18920610 0.82 ANPEP (0.71) ANPEPENPEPTPH1ALDH1A1TSHR
SCHEMBL28913867 0.82 PLA2G10 (0.48) ANPEPENPEPPLA2G10PLA2G2APARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed
WO-2017093272-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L ANPEP 3136/4885ENPEP 4174/4885PLA2G10 3401/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L ANPEP 3136/4885ENPEP 4174/4885PLA2G10 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.